Sign In
Buy PTGX
$95.41
+2.18 (+2.34%)
At Close: Jun 03, 2026
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma
08:05am, Tuesday, 10'th Aug 2021
NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Z
NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the "Res
NEWARK, Calif., June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwr
Protagonist Therapeutics (PTGX) Stock Jumps 9.3%: Will It Continue to Soar?
09:46am, Thursday, 17'th Jun 2021
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock
09:07pm, Tuesday, 15'th Jun 2021
NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underw
Protagonist Therapeutics Announces Proposed Public Offering of Common Stock
05:00pm, Monday, 14'th Jun 2021
NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public of
Protagonist Stock Moves Higher As Rusfertide Shows Durability Of Effect, Symptom Improvements In Blood Cancer Trial
02:09pm, Friday, 11'th Jun 2021
Protagonist Therapeutics Inc (NASDAQ: PTGX) has announced updated results from the ongoing Phase 2 study of rusfertide for polycythemia vera (PV), a type of blood cancer. Data were presented at the
Protagonist Therapeutics Announces Updated Phase 2 Data Supporting Long-Term Efficacy of Rusfertide in Polycythemia Vera
07:00am, Friday, 11'th Jun 2021
NEWARK, Calif., June 11, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today announced updated results from the ongoing Phase 2 study of rusfertide, an
NEWARK, Calif., June 7, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that management will host an investor conference call and webca
Protagonist Therapeutics Announces First Subject Dosed in Phase 1 Study of Oral IL-23 Receptor Antagonist PN-232
07:00am, Monday, 24'th May 2021
NEWARK, Calif., May 24, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first human subject has been dosed in a Phase 1 study of PN-232, a novel oral inte
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
07:32pm, Tuesday, 04'th May 2021
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Protagonist Reports First Quarter 2021 Financial Results and Provides Corporate Update
04:01pm, Tuesday, 04'th May 2021
NEWARK, Calif., May 4, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first quarter of 2021 ended March 31, 2021
Protagonist Therapeutics Reports Granting of Inducement Award
05:47pm, Monday, 03'rd May 2021
NEWARK, Calif., May 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently h
NEWARK, Calif., March 22, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that the Division of Nonmalignant Hematology at the U.S. Food an
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call Transcript
10:12pm, Wednesday, 10'th Mar 2021
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2020 Results - Earnings Call Transcript
